Overview

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

CytRx

Treatments:

Doxorubicin